Posted by Reuters: Business News on January 3, 2012
JERUSALEM (Reuters) – Teva Pharmaceutical Industries’ new chief executive is set to shift the company’s focus to branded drugs from generics as he imports a successful strategy of making mid-sized deals from Bristol-Myers Squibb.
Posted by Reuters: Business News on August 22, 2011
LONDON (Reuters) – Despite being third to market, a new bloodthinner from Bristol-Myers Squibb and Pfizer may become the biggest seller in an emerging multibillion-dollar class of drugs for preventing strokes in heart patients.
Posted by Reuters: Business News on June 7, 2010
NEW YORK/LONDON (Reuters) – Bristol-Myers Squibb Co’s shares rose more than 8 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.
Posted by Reuters: Business News on March 4, 2010
NEW YORK (Reuters) – Bristol-Myers Squibb Co set a baseline for profits in 2013 as it provided investors their first glimpse of life after Plavix, the world’s second-bestselling drug.
